Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus VIGAFYDE.
PARADIONE vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
100 mg orally three times daily; maximum 600 mg/day.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant